0000886163-18-000132.txt : 20180905 0000886163-18-000132.hdr.sgml : 20180905 20180905200013 ACCESSION NUMBER: 0000886163-18-000132 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180904 FILED AS OF DATE: 20180905 DATE AS OF CHANGE: 20180905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Berkman Charles S CENTRAL INDEX KEY: 0001392266 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 181056470 MAIL ADDRESS: STREET 1: 11085 NORTH TORREY PINES ROAD STREET 2: SUITE 300 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2018-09-04 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001392266 Berkman Charles S 3911 SORRENTO VALLEY BOULEVARD, STE 110 SAN DIEGO CA 92121 0 1 0 0 SVP, Gen. Counsel & Secretary Common Stock 2018-09-04 4 M 0 469 21.92 A 28232 D Common Stock 2018-09-04 4 M 0 5985 74.42 A 34217 D Common Stock 2018-09-04 4 M 0 7077 56.26 A 41294 D Common Stock 2018-09-04 4 M 0 5886 85.79 A 47180 D Common Stock 2018-09-04 4 S 0 19417 254.9861 D 27763 D Employee Stock Option (right to buy) 56.26 2018-09-04 2018-09-04 4 M 0 7077 0.0 D 2025-02-10 Common Stock 7077 3292 D Employee Stock Option (right to buy) 74.42 2018-09-04 2018-09-04 4 M 0 5985 0.0 D 2024-02-12 Common Stock 5985 1931 D Employee Stock Option (right to buy) 85.79 2018-09-04 2018-09-04 4 M 0 5886 0.0 D 2026-02-11 Common Stock 5886 4577 D Non-Qualified Stock Option (right to buy) 21.92 2018-09-04 2018-09-04 4 M 0 469 0.0 D 2023-02-15 Common Stock 469 0 D The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.85 to $256.59, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/10/15. Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/12/14. Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/11/16. Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/15/13. Charles S. Berkman 2018-09-05